Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Range-bound action ⢠Support holding ⢠Resistance capped Support Level: $51.60-$51.72 Resistance Level: $55.14-$55.22 ALKS has been mostly range-bound over the last month, holding support around $51.60-$51.72 but staying capped near $55.14-$55.22, so a breakout above resistance is needed to confirm stronger momentum.
Sentiment & News
Key News Insights: ⢠Pipeline progress ⢠Earnings beat hopes ⢠Near-term catalyst Alkermes is drawing positive attention from encouraging alixorexton long-term data and expectations for a Q2 earnings beat ahead of its July 28 report.
AI Summary
ALKS has shifted from a pure pipeline bet to a commercially supported neuroscience story with encouraging alixorexton/LUMRYZ progress and ~16% expected Q2 revenue growth, but the stock already appears to price in much of that upside, so the key takeaway is to wait for earnings confirmation that growth is durable before expecting a re-rating.
Description
Alkermes plc is a Dublin-based biopharmaceutical company that develops and commercializes medicines for psychiatric and neurological disorders and has operations in the United States, Ireland and other markets. Its commercial portfolio includes long-acting injectable and oral treatments for schizophrenia, bipolar disorder and substance-use disorders, as well as a product for relapsing forms of multiple sclerosis. The company maintains a pipeline that includes an oral atypical antipsychotic candidate and an engineered immunotherapy for oncology, and it holds collaboration agreements with Janssen entities.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 2 | Apr 9 | ALKS | Alkermes plc | Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds. | Closed | +0.2% |